JP2009528985A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009528985A5 JP2009528985A5 JP2008552918A JP2008552918A JP2009528985A5 JP 2009528985 A5 JP2009528985 A5 JP 2009528985A5 JP 2008552918 A JP2008552918 A JP 2008552918A JP 2008552918 A JP2008552918 A JP 2008552918A JP 2009528985 A5 JP2009528985 A5 JP 2009528985A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- trkb
- agonist
- trkb agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 29
- 239000000556 agonist Substances 0.000 claims 20
- 101100127166 Escherichia coli (strain K12) kefB gene Proteins 0.000 claims 16
- 241000288906 Primates Species 0.000 claims 12
- 208000016261 weight loss Diseases 0.000 claims 6
- 230000004580 weight loss Effects 0.000 claims 6
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 4
- 206010006895 Cachexia Diseases 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 4
- 206010047700 Vomiting Diseases 0.000 claims 4
- 230000032683 aging Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
Claims (33)
- 末梢投与される有効量のNT−4/5を含む、霊長類における悪液質を治療するための薬学的組成物。
- 前記霊長類がヒトである、請求項1に記載の薬学的組成物。
- 末梢投与される有効量のNT−4/5を含む、霊長類における神経性食欲不振を治療するための薬学的組成物。
- 前記霊長類がヒトである、請求項3に記載の薬学的組成物。
- 末梢投与される有効量のNT−4/5を含む、哺乳動物におけるオピオイド誘導性嘔吐症を治療するための薬学的組成物。
- 前記哺乳動物がヒトである、請求項5に記載の薬学的組成物。
- 末梢投与される有効量のtrkBアゴニストを含む、霊長類における悪液質を治療するための薬学的組成物。
- 前記霊長類がヒトである、請求項7に記載の薬学的組成物。
- 前記trkBアゴニストが抗trkBアゴニスト抗体である、請求項7または8に記載の薬学的組成物。
- 前記アゴニストがtrkB選択的である、請求項7から9のいずれかに記載の薬学的組成物。
- 末梢投与される有効量のtrkBアゴニストを含む、霊長類における神経性食欲不振を治療するための薬学的組成物。
- 前記霊長類がヒトである、請求項11に記載の薬学的組成物。
- 前記trkBアゴニストが抗trkBアゴニスト抗体である、請求項11または12に記載の薬学的組成物。
- 前記アゴニストがtrkB選択的である、請求項11から13のいずれかに記載の薬学的組成物。
- 末梢投与される有効量のtrkBアゴニストを含む、哺乳動物におけるオピオイド誘導性嘔吐症を治療するための薬学的組成物。
- 前記哺乳動物がヒトである、請求項15に記載の薬学的組成物。
- 前記trkBアゴニストが抗trkBアゴニスト抗体である、請求項15または16に記載の薬学的組成物。
- 前記アゴニストがtrkB選択的である、請求項15から17のいずれかに記載の薬学的組成物。
- 悪液質、神経性食欲不振、望まれない体重減少、またはオピオイド誘導性嘔吐症を治療するための末梢投与用医薬の製造への、NT−4/5またはその薬学的に許容できる塩の使用。
- 悪液質、神経性食欲不振、望まれない体重減少、またはオピオイド誘導性嘔吐症を治療するための末梢投与用医薬の製造への、trkBアゴニストまたはその薬学的に許容できる塩の使用。
- 前記trkBアゴニストがtrkB選択的である、請求項20に記載の使用。
- 前記trkBアゴニストが抗trkBアゴニスト抗体である、請求項20または21に記載の使用。
- 末梢投与される有効量のNT−4/5を含む、霊長類における望まれない体重減少を治療するための薬学的組成物。
- 前記霊長類がヒトである、請求項23に記載の薬学的組成物。
- 前記望まれない体重減少が、加齢に関連する、請求項23または24に記載の薬学的組成物。
- 前記ヒトが、約25.0kg/m2、約24.0kg/m2、約23.0kg/m2、約22.0kg/m2、約21.0kg/m2、約20kg/m2、約19.0kg/m2、および約18.5kg/m2のいずれか未満のボディーマスインデックスを有する、請求項2、24、または25のいずれか1項に記載の薬学的組成物。
- 末梢投与される有効量のtrkBアゴニストを含む、霊長類における望まれない体重減少を治療するための薬学的組成物。
- 前記霊長類がヒトである、請求項27に記載の薬学的組成物。
- 前記trkBアゴニストが抗trkBアゴニスト抗体である、請求項27または28に記載の薬学的組成物。
- 前記アゴニストがtrkB選択的である、請求項27から29のいずれか1項に記載の薬学的組成物。
- 前記ヒトが、約25.0kg/m2、約24.0kg/m2、約23.0kg/m2、約22.0kg/m2、約21.0kg/m2、約20kg/m2、約19.0kg/m2、および約18.5kg/m2のいずれか未満のボディーマスインデックスを有する、請求項8から10または28から30のいずれか1項に記載の薬学的組成物。
- 前記望まれない体重減少が、加齢に関連する、請求項27から31のいずれか1項に記載の薬学的組成物。
- 前記ヒトが、約18.5kg/m2、約17.5kg/m2、または約16.5kg/m2のいずれか未満のボディーマスインデックスを有する、請求項4または12から14のいずれか1項に記載の薬学的組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76541006P | 2006-02-02 | 2006-02-02 | |
PCT/IB2007/000254 WO2007088476A1 (en) | 2006-02-02 | 2007-02-01 | Methods for treating unwanted weight loss or eating disorders by administering a trkb agonist |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009528985A JP2009528985A (ja) | 2009-08-13 |
JP2009528985A5 true JP2009528985A5 (ja) | 2009-10-15 |
Family
ID=38093467
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008552918A Withdrawn JP2009528985A (ja) | 2006-02-02 | 2007-02-01 | trkBアゴニストを投与することにより望まれない体重減少または摂食障害を治療する方法 |
Country Status (17)
Country | Link |
---|---|
US (2) | US20070248611A1 (ja) |
EP (1) | EP1988923A1 (ja) |
JP (1) | JP2009528985A (ja) |
KR (1) | KR20080091838A (ja) |
CN (1) | CN101400367A (ja) |
AR (1) | AR059304A1 (ja) |
AU (1) | AU2007210862A1 (ja) |
BR (1) | BRPI0707482A2 (ja) |
CA (1) | CA2637826A1 (ja) |
DO (1) | DOP2007000021A (ja) |
IL (1) | IL193069A0 (ja) |
NL (1) | NL2000464C2 (ja) |
PE (1) | PE20071364A1 (ja) |
RU (1) | RU2008131939A (ja) |
TW (1) | TW200808352A (ja) |
UY (1) | UY30128A1 (ja) |
WO (1) | WO2007088476A1 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050209148A1 (en) * | 2004-02-20 | 2005-09-22 | Arnon Rosenthal | Methods of treating obesity or diabetes using NT-4/5 |
KR20090088896A (ko) * | 2006-11-09 | 2009-08-20 | 아이알엠 엘엘씨 | 효현제 trkb 항체 및 그의 용도 |
JP2010513461A (ja) * | 2006-12-20 | 2010-04-30 | ライナット ニューロサイエンス コーポレイション | 自己免疫障害を治療するためのTrkBアゴニスト |
CA2703329A1 (en) * | 2007-10-23 | 2009-04-30 | Novartis Ag | Use of trkb antibodies for the treatment of respiratory disorders |
WO2010086828A2 (en) * | 2009-02-02 | 2010-08-05 | Rinat Neuroscience Corporation | Agonist anti-trkb monoclonal antibodies |
FR2942409B1 (fr) * | 2009-02-20 | 2013-07-26 | Natacha Voillot | Composition pharmaceutique pour la prevention des avortements a repetition. |
GB2491106A (en) | 2011-05-18 | 2012-11-28 | Univ Basel | Antibodies against tropomyosin-related kinase B receptors |
CN102944674B (zh) * | 2012-11-05 | 2014-10-22 | 武汉远征世纪制药有限公司 | 一种检测TrkB受体pan-Tyr位点活性的ELISA试剂盒及其使用方法 |
WO2017085035A1 (en) | 2015-11-17 | 2017-05-26 | Glaxosmithkline Intellectual Property Development Limited | Binding agonists for treatment of neurological and other disorders |
US9914781B1 (en) | 2016-11-08 | 2018-03-13 | Glaxosmithkline Intellectual Property Development Limited | Binding agonist for treatment of neurological and other disorders |
WO2019108662A1 (en) * | 2017-11-30 | 2019-06-06 | Regeneron Pharmaceuticals, Inc. | Anti-trkb monoclonal antibodies and methods of use |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US5109113A (en) * | 1986-05-02 | 1992-04-28 | Genentech, Inc. | Membrane anchor fusion polypeptides |
US4777127A (en) * | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
US5219740A (en) * | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
US5364768A (en) * | 1987-07-07 | 1994-11-15 | Farmitalia Carlo Erba S.R.L. | Process for the preparation of penems |
US5422120A (en) * | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
US5686579A (en) * | 1988-06-21 | 1997-11-11 | Hybrisens, Ltd. | Use of antibody/antigen interactions to protect biologically active proteins and peptides |
DE69033975T2 (de) * | 1989-01-23 | 2002-10-02 | Chiron Corp | Rekombinanttherapien für Infektionen und hyperproliferative Störungen |
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US6673776B1 (en) * | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
JPH03133378A (ja) * | 1989-07-19 | 1991-06-06 | Modrovich Ivan E | 被験体を安定化させて液体中でのその生物学的活性を保存する方法 |
US5644034A (en) * | 1989-08-07 | 1997-07-01 | Peptide Technology Ltd. | Tumour necrosis factor binding ligands |
US5240846A (en) * | 1989-08-22 | 1993-08-31 | The Regents Of The University Of Michigan | Gene therapy vector for cystic fibrosis |
US5670488A (en) * | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
US6566091B1 (en) * | 1990-09-25 | 2003-05-20 | Genentech, Inc. | Neurotrophic factor |
US5364769A (en) * | 1990-09-25 | 1994-11-15 | Genentech, Inc. | Nucleic acid encoding neurotrophic factor four (NT-4), vectors, host cells and methods of production |
DK0550665T3 (da) * | 1990-09-25 | 1996-12-02 | Genentech Inc | Ny neurotrofisk faktor |
US6506728B2 (en) * | 1990-09-25 | 2003-01-14 | Genentech, Inc. | Methods using a novel neurotrophic factor, NT-4 |
DK0487301T3 (da) * | 1990-11-20 | 2000-09-18 | Dade Behring Marburg Gmbh | Fremgangsmåde til stabilisering af enzymkonjugater |
US20030134815A1 (en) * | 1991-08-20 | 2003-07-17 | The Govt. Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services | Adenovirus mediated transfer of genes to the gastrointestinal tract |
WO1993010218A1 (en) * | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
FR2688514A1 (fr) * | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
CA2143739A1 (en) * | 1992-09-07 | 1994-03-17 | Andrew T. Holder | Growth hormone potentiating molecules |
WO1994006455A1 (en) * | 1992-09-14 | 1994-03-31 | Regeneron Pharmaceuticals, Inc. | Method of producing analgesia using neurotrophins |
US5349056A (en) * | 1992-10-09 | 1994-09-20 | Regeneron Pharmaceuticals | Modified ciliary neurotrophic factors |
IL109280A0 (en) * | 1993-04-15 | 1994-07-31 | Regeneron Pharma | Neurotrophins for treatment of depression |
US5759573A (en) * | 1993-04-22 | 1998-06-02 | Depotech Corporation | Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use |
JP2534968B2 (ja) * | 1993-05-27 | 1996-09-18 | チッソ株式会社 | フラビン還元酵素遺伝子 |
US6015686A (en) * | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
US5766627A (en) * | 1993-11-16 | 1998-06-16 | Depotech | Multivescular liposomes with controlled release of encapsulated biologically active substances |
US5753225A (en) * | 1993-12-03 | 1998-05-19 | The Regents Of The University Of California | Antibodies that mimic actions of neurotrophins |
US6024734A (en) * | 1994-03-31 | 2000-02-15 | Brewitt; Barbara A. | Treatment methods using homeopathic preparations of growth factors |
US20030191061A1 (en) * | 1994-03-31 | 2003-10-09 | Brewitt Barbara A. | Treatment methods using homeopathic preparations of growth factors |
US6436908B1 (en) * | 1995-05-30 | 2002-08-20 | Duke University | Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function |
US6013517A (en) * | 1994-05-09 | 2000-01-11 | Chiron Corporation | Crossless retroviral vectors |
AU2589095A (en) * | 1994-05-16 | 1995-12-05 | Washington University | Cell membrane fusion composition and method |
AU689920B2 (en) * | 1994-06-24 | 1998-04-09 | Dade Behring Marburg Gmbh | Method of stabilizing molecules, or parts of molecules, which are sensitive to hydrolysis |
US5770577A (en) * | 1994-11-14 | 1998-06-23 | Amgen Inc. | BDNF and NT-3 polypeptides selectively linked to polyethylene glycol |
US6143718A (en) * | 1995-06-07 | 2000-11-07 | Amylin Pharmaceuticals, Inc. | Treatment of Type II diabetes mellutis with amylin agonists |
US6090382A (en) * | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
US5780484A (en) * | 1996-11-13 | 1998-07-14 | Vertex Pharmaceuticals Incorporated | Methods for stimulating neurite growth with piperidine compounds |
US5840736A (en) * | 1996-11-13 | 1998-11-24 | Vertex Pharmaceuticals Incorporated | Methods and compositions for stimulating neurite growth |
ES2293662T3 (es) | 1996-11-15 | 2008-03-16 | Genentech, Inc. | Purificacion de neurotrofinas. |
CN1250379A (zh) * | 1997-01-23 | 2000-04-12 | 住友制药株式会社 | 糖尿病治疗剂 |
US20030105057A1 (en) * | 1997-03-19 | 2003-06-05 | Yale University | Methods and compositions for stimulating apoptosis and cell death or for inhibiting cell growth and cell attachment |
US8173127B2 (en) * | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
IL134536A0 (en) * | 1997-08-29 | 2001-04-30 | Vertex Pharma | Compounds possessing neuronal activity and pharmaceutical compositions containing the same |
AU9692198A (en) * | 1997-10-10 | 1999-05-03 | Kevin J. Donahue | Gene delivery compositions and methods |
US6565874B1 (en) * | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
PT1409654E (pt) * | 1999-06-16 | 2008-11-25 | Boston Biomedical Res Inst | Controlo imunológico dos níveis de beta-amilóide in vivo |
JP2004510684A (ja) * | 1999-07-06 | 2004-04-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | 神経学的疾患の治療のためのアゾアミノ酸誘導体 |
JP2003503476A (ja) * | 1999-07-06 | 2003-01-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | 環化アミド誘導体 |
JP2003503484A (ja) * | 1999-07-06 | 2003-01-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | アミノアルキル誘導体 |
WO2001002405A1 (en) * | 1999-07-06 | 2001-01-11 | Vertex Pharmaceuticals Incorporated | Quinuclidine derivatives for treatment of neurological disorders |
JP2003503482A (ja) * | 1999-07-06 | 2003-01-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | 環化アミノ酸誘導体 |
WO2001008685A1 (en) * | 1999-07-30 | 2001-02-08 | Vertex Pharmaceuticals Incorporated | Acyclic and cyclic amine derivatives |
DK1223966T3 (da) * | 1999-10-29 | 2003-08-18 | Bioph Biotech Entw Pharm Gmbh | Anvendelse af GDNF til behandling af hornhindedefekter |
WO2001060398A1 (fr) * | 2000-02-18 | 2001-08-23 | Sumitomo Pharmaceuticals Company, Limited | Medicaments destines a ameliorer l'intolerance au glucose |
EP1262189A1 (en) * | 2000-03-06 | 2002-12-04 | Sumitomo Pharmaceuticals Company, Limited | Leptin-resistance ameliorating agents |
DE60140252D1 (de) | 2000-06-22 | 2009-12-03 | Genentech Inc | Agonistische monoklonale antikörper gegen trkc |
US7060429B2 (en) * | 2001-02-22 | 2006-06-13 | University Of Maryland, Baltimore | Treatment of neurodegenerative diseases by altering levels of TrkB isoforms and/or TrkC isoforms |
CN1529599A (zh) * | 2001-06-14 | 2004-09-15 | ��̩��˹ҩ��ɷ�����˾ | 可用于治疗神经元损伤的无环哌嗪和哌啶衍生物 |
US6818613B2 (en) * | 2001-11-07 | 2004-11-16 | Ortho-Mcneil Pharmaceutical, Inc. | Aqueous sustained-release formulations of proteins |
US20050209148A1 (en) * | 2004-02-20 | 2005-09-22 | Arnon Rosenthal | Methods of treating obesity or diabetes using NT-4/5 |
-
2007
- 2007-02-01 TW TW096103977A patent/TW200808352A/zh unknown
- 2007-02-01 WO PCT/IB2007/000254 patent/WO2007088476A1/en active Application Filing
- 2007-02-01 EP EP07705526A patent/EP1988923A1/en not_active Withdrawn
- 2007-02-01 KR KR1020087021272A patent/KR20080091838A/ko not_active Application Discontinuation
- 2007-02-01 NL NL2000464A patent/NL2000464C2/nl not_active IP Right Cessation
- 2007-02-01 CN CNA2007800083943A patent/CN101400367A/zh active Pending
- 2007-02-01 DO DO2007000021A patent/DOP2007000021A/es unknown
- 2007-02-01 BR BRPI0707482-4A patent/BRPI0707482A2/pt not_active IP Right Cessation
- 2007-02-01 AU AU2007210862A patent/AU2007210862A1/en not_active Abandoned
- 2007-02-01 US US11/670,096 patent/US20070248611A1/en not_active Abandoned
- 2007-02-01 RU RU2008131939/14A patent/RU2008131939A/ru not_active Application Discontinuation
- 2007-02-01 CA CA002637826A patent/CA2637826A1/en not_active Abandoned
- 2007-02-01 JP JP2008552918A patent/JP2009528985A/ja not_active Withdrawn
- 2007-02-02 UY UY30128A patent/UY30128A1/es not_active Application Discontinuation
- 2007-02-02 AR ARP070100454A patent/AR059304A1/es not_active Application Discontinuation
- 2007-02-02 PE PE2007000122A patent/PE20071364A1/es not_active Application Discontinuation
-
2008
- 2008-07-24 IL IL193069A patent/IL193069A0/en unknown
-
2009
- 2009-07-23 US US12/508,379 patent/US20090291897A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009528985A5 (ja) | ||
WO2011053792A3 (en) | Methods and compositions for sustained delivery of drugs | |
JP2009522296A5 (ja) | ||
WO2006102374A3 (en) | Bioactive wide-weave mesh | |
EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
EP1991218A4 (en) | USE OF CYCLOLIGNANS IN THE TREATMENT OF TYPE 2 DIABETES AND AS CONTRACEPTIVES | |
IL197420A (en) | Polymorphic form of 4 - [3 - (4 - cyclopropanecarbonyl - piperazine - 1 - carbonyl) - 4 - fluoro - benzyl] - h2 - phthalazine - 1 - on, methods of preparation, a pharmaceutical preparation containing it and uses in this form to prepare drugs for the treatment of the human body | |
HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
HRP20151230T1 (hr) | Liksisenatid kao dodatak metforminu kod lijeäśenja dijabetesa tipa 2 | |
WO2006017188A3 (en) | Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients | |
JP2014530874A5 (ja) | ||
MX339614B (es) | Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2. | |
JP2009525343A5 (ja) | ||
JP2009280621A5 (ja) | ||
JP2016147915A5 (ja) | ||
RU2008131939A (ru) | Способы лечения нежелательной потери веса или нарушений приема пищи агонистами trkb | |
HRP20140745T1 (hr) | Uporaba amisulprida za lijeäśenje kemoterapijom izazvane muäśnine i povraä†anja | |
EP4324454A3 (en) | Cross-linking agents and associated methods | |
RU2004135563A (ru) | Лекарственное средство для лечения повышенной активности мочевого пузыря | |
WO2015070234A3 (en) | Neuroprotective compounds and use thereof | |
WO2017182873A3 (en) | Peptide-oligourea foldamer compounds and methods of their use | |
JP2011500589A5 (ja) | ||
DK2802319T3 (da) | Fastdosiskombinationsterapi for parkinsons sygdom | |
CL2007003484A1 (es) | Composicion farmaceutica que comprende valsartan y un tensoactivo, un componente lipofilico y un componente hidrofilico; procedimiento de preparacion; y uso en el tratamiento de la insuficiencia cardiaca, angina, infarto de miocardio, arterioescleros | |
IL194500A0 (en) | Peptide substance enhancing capillaries resistance, pharmaceutical composition on its base and method of its application |